Liver fibrosis in chronic liver disease (CLD) results in complex alterations in procoagulant and anticoagulant proteins. Although an elevated international normalized ratio (INR) is a prominent feature of progressive fibrosis, the utility of the INR to accurately reflect the net effect of these changes on the coagulation system is uncertain. In subjects with CLD, elevated INRs have been observed in both bleeding and thrombotic complications, suggesting limitations of the INR in characterizing the coagulation status. Unlike the INR, which is preferentially sensitive to the extrinsic pathway, the direct measurement of thrombin generation better captures the global coagulation cascade. We conducted a pilot study measuring the INR, chromogenic factor X and thrombin generation in CLD subjects and compared them with control subjects and subjects on warfarin anticoagulation. We observed a large interquartile range in thrombin generation among compensated CLD subjects across a narrow INR range, suggesting that the INR is a suboptimal surrogate measure of thrombin generation in CLD subjects. Blood Coagul Fibrinolysis 26:844-847
Introduction
The liver is responsible for the synthesis and clearance of proteins involved in the coagulation cascade. Synthetic dysfunction of liver fibrosis results in complex alterations in procoagulant and anticoagulant proteins that are reflected by an elevated international normalized ratio (INR) [1] . Alterations in hemostasis and coagulation proteins include a thrombocytopenic state, reduction of procoagulants factor II, V, VII, IX, X, XI, XII, and the natural inhibitors, antithrombin, protein C, protein S and dysfibrinogenemia.
On the contrary, the utility of the INR to accurately reflect the net effect of these changes on the coagulation system is less certain. The INR was originally developed to monitor the depth of warfarin anticoagulation and has been conveniently adapted to the chronic liver disease (CLD) population as a measure of coagulation function [2] . In the clinical setting, elevations in the INR resulting from liver fibrosis are frequently encountered in both bleeding and thrombotic settings that are exemplified by upper gastrointestinal bleeding and intra-abdominal thrombosis with progressive liver fibrosis. Taken together, this suggests limitations of the INR in characterizing the coagulation function in CLD subjects. Unlike the INR, which is preferentially sensitive to the extrinsic pathway, the measurement of thrombin generation is a superior method to capture the global coagulation cascade [3] . Therefore, our pilot study sought to characterize thrombin generation, chromogenic factor X (cFX) and the INR in CLD subjects and compared them with control subjects and subjects on warfarin anticoagulation.
Methods
We prospectively recruited medically stable subjects seen in the ambulatory setting at the University of Pittsburgh Medical Center (Montefiore/Presbyterian-Shadyside) from March 2013 to May 2014. This study was approved by the institutional review board at the University of Pittsburgh. Thirty-four patients were recruited into the three study groups comprising of CLD (n ¼ 9), warfarin subjects (n ¼ 14) and control (n ¼ 11). Indications for warfarin anticoagulation were for fibrillation and venous thromboembolism. Peripheral blood were drawn from subjects into citrated blood collection tubes and centrifuged to obtain plasma. Thrombin generation assay was performed using the technothrombin thrombin generation assay (diaPharma, West Chester, Ohio, USA) using RC low phospholipids reagent. Reactions assessed on a Synergy HT fluorometer (BioTek, Winooski, Vermont, USA) and data were analyzed using the Technothrombin thrombin generation assay software. The area under curve (AUC) plotted, representing thrombin generation was assessed. INR was performed using the Innovin reagent (Siemens, Tarrytown, New York, USA) on the BCS-XP instrument (Siemens). cFX was performed using the cFX kit (diapharma) on a BCS-XP instrument using Standard Human Plasma (Siemens) as calibration standard. Statistical analysis was performed using SPSS Version 22 (SPSS Inc, Chicago, Illinois, USA). Spearman rho correlations were utilized to assess relationships between continuous variables.
Results
The INR demonstrated an inverse correlation with cFX in both warfarin (r ¼ À0.63, P ¼ 0.017) and CLD (r ¼ À0.87, P ¼ 0.002) subjects. In Fig. 1 , the respective cFX activity measured within control, warfarin and CLD subjects ranged from 81 to 172% (median, M ¼ 119%), 22 to 93% (M ¼ 40%) and 27 to 80% (M ¼ 44%). As validated in previous studies, warfarin subjects with therapeutic INR of 2.0-3.5 had cFX activity between 24 and 48% (mean, m ¼ 35), which corresponded to 20-35% of cFX activity observed in the control group (m ¼ 126%).
The inverse relationship observed between the INR and cFX also extended to thrombin generation. The INR demonstrated an inverse correlation to thrombin generation in both warfarin (r ¼ À0.85, P < 0.001) and CLD (r ¼ À0.73, P ¼ 0.025) subjects. The respective thrombin generation measured across control, warfarin subjects on therapeutic anticoagulation with INR 2.0-3.5 and CLD subjects ranged from 3000 to 4072 nmol/l Â min (M ¼ 3221 nmol/l Â min), 49 to 1487 nmol/l Â min (M ¼ 401 nmol/l Â min) and 210 to 2853 nmol/l Â min (M ¼ 1539 nmol/l Â min). As shown in Fig. 2 , warfarin subjects on therapeutic anticoagulation consistently demonstrate diminished levels below 600 nmol/l Â min. Compared with thrombin generation in control and warfarin subjects, thrombin generation in CLD subjects exhibited a large interquartile range (IQR) across the measured INR (CLD: 1700 nmol/l Â min vs. control: 580 nmol/l Â min vs. warfarin: 290 nmol/l Â min).
Lastly, we compared thrombin generation and cFX correlations within the same study groups by placing our Spearman rho correlations into a Hotelling's t test. In warfarin users, the correlation between INR and cFX was not significantly different from the correlation between INR and thrombin generation (P ¼ 0.157). Similarly, there was no difference in the INR correlation between the thrombin generation and cFX in the CLD patients. This finding was expected as the pairs of correlations were similarly strong and negative, as described above.
Discussion
Thrombin serves critical roles in hemostasis and thrombosis [3] . In patients with CLD, measuring plasma's ability to generate thrombin provides a better account of the net effects of elements involved in the forward Plasma from chronic liver disease subjects exhibit differential ability to generate thrombin Yang et al. 845 reactions, reserve reactions and natural inhibitors of coagulation. Therefore, thrombin generation may provide greater fidelity in characterizing coagulation status compared with the INR. The measurement of thrombin formation relies on the measurement of a fluorogenic substrate obtained via the activation of the coagulation cascade by tissue factor. The total area under the curve derived from this measurement over time gives the total thrombin generated, also known as the endogenous thrombin potential. Efforts to validate the use of thrombin generation in the clinical setting are ongoing with active research in numerous areas, including the hemophilia population. Unlike thrombin generation, the clinical application of cFX has been validated. The cFX assay represents a phospholipid-independent method of determining the activity of factor X. For example, the cFX assay is frequently used in monitoring warfarin anticoagulation in subjects with lupus anticoagulant, which interferes with the phospholipid-dependent INR testing. Other uses of cFX include guiding transition from direct thrombin inhibitors to warfarin and accurately monitoring warfarin therapy in dysfibrinogenemia where the interference of fibrin endpoint creates a falsely elevated INR [4, 5] .
In our pilot study, we observed a large IQR in thrombin generation among compensated CLD subjects across a narrow INR range. This observation contrasts against those IQR observed in control and warfarin subjects. This preliminary finding suggests that the INR is a suboptimal surrogate measure of thrombin generation in CLD subjects. Given the wide variation in thrombin generation identified from our CLD subjects, we hypothesize that thrombin generation characterization in CLD subjects may allow for stratification of CLD subjects who are either at an increased thrombotic risk or increased bleeding risk.
We must note that almost three-quarters of our CLD subjects had alcohol liver disease as their primary liver disease cause. The limited data set in this preliminary evaluation precludes us from investigating differences across the various CLD causes. However, regardless of its causes, CLD is characterized by progressive stages of liver fibrosis and tissue remodeling leading to end-stage cirrhosis. We postulate that the stages of fibrotic remodeling may mirror the decrease in synthesis of coagulation factors wherein new investigational coagulation tests may be a superior measure than to the INR. This has clinical relevance because the INR is one parameter that is incorporated into the model for endstage liver disease (MELD) score, which is a well validated predictor for survival. It remains to be determined whether the substitution of the thrombin generation for the INR within the MELD score may improve on predicting survival in the CLD population. 
